
Orphazyme will be scrutinizing its expenses after the US Food and Drug Authority, the FDA, rejected its main candidate arimoclomol for the treatment of the metabolic disease Niemann-Pick type C, also known as NPC.
According to Orphazyme's CEO Christophe Bourdon, the company has started looking into what will happen to the US organization, in which it has invested large sums in recent months in order to prepare for the potential launch. The rejection from the FDA, announced on Friday, has turned this into more of a long-term prospect.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app